about
Homocamptothecins: E-ring modified CPT analogues.Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.CDC25 inhibitors as anticancer agents are moving forward.Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.A novel synthetic inhibitor of CDC25 phosphatases: BN82002.Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.Determination of the anti-platelet-activating factor BN-50727 and metabolites in human urine by high-performance liquid chromatography using solid-phase extractionDetermination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extractionBN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase IIThe homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitorThe dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growthHomocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditionsHomocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan]
P50
Q34149062-D167DB28-4D6C-4BF7-B67D-8E2854220663Q34646365-65AE77A7-CAA6-4C0C-BD80-E964FDB74BB1Q37347038-0B00A31A-D368-4837-9806-4A9350C8B41EQ40363451-67528D15-68C5-4D68-9F96-A197E097CFD2Q40559090-D8F61BCB-663E-4EB9-A573-AB89C083C0DCQ40916716-DA3F062E-D28B-402A-B93F-FE92182BCBEFQ43837060-041FBB6B-5F4C-4983-9CB2-3861090BBAB8Q46709580-6B954D05-6183-4D95-A4D0-F7D1A35EC393Q54049254-7EBFBA71-74CA-446C-875B-716182B6DF74Q71251364-8D707DEB-34E4-4364-82EF-49DB0B0956BCQ71795171-A85DF69A-3348-4AB9-841C-40B8FBDCBB7FQ73022481-4C71F6C2-080D-41FA-A70E-81887868278BQ73476623-E456C582-A75A-42CD-8CBD-B8129F473E72Q73476626-5D8CE42E-8BB2-46D3-AD7D-505FD8CCDFF9Q73707470-2642B5D8-E738-4EA4-898A-0A8D03DDB160Q77755489-E433EFD2-AFA4-4ED9-A77A-8CAFA21ADCFEQ77948963-04B027FA-B5B4-438A-919D-F058E349B39F
P50
description
researcher
@en
wetenschapper
@nl
name
O Lavergne
@en
O Lavergne
@nl
type
label
O Lavergne
@en
O Lavergne
@nl
prefLabel
O Lavergne
@en
O Lavergne
@nl
P106
P108
P31
P496
0000-0003-4922-5086